Nuvalent, Inc.
NUVL
Rangering i aksjer
#2114
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Aksjekurs
$123.96
Sist synkronisert: 2026-07-21
Markedsverdi
$9.75B
Endring (1 dag)
0.00%
Endring (1 år)
27.56%
Land
US
Handel Nuvalent, Inc. (NUVL)
Kategori
Healthcare
Antall utestående aksjer for Nuvalent, Inc. (NUVL)
Antall utestående aksjer per March 2026: 78.67M
Ifølge Nuvalent, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 78.67M. Ved slutten av December 2023 hadde selskapet 58.22M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Nuvalent, Inc. (NUVL) fra 2019 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 78.67M | 18.46% |
| 2024 | 66.41M | 14.06% |
| 2023 | 58.22M | 17.22% |
| 2022 | 49.67M | 128.02% |
| 2021 | 21.78M | -4.73% |
| 2020 | 22.86M | -52.65% |
| 2019 | 48.28M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 222.74% |
US
|
|
| 396.00M | 403.37% |
US
|
|
| 478.91M | 508.76% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -20.95% |
NL
|
